GENMARK DIAGNOSTICS, INC. (NASDAQ:GNMK) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
GenMark Diagnostics, Inc. Exhibit
EX-99.1 2 exhibit991622020.htm EX-99.1 DocumentExhibit 99.1AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENTThis Amended and Restated Executive Employment Agreement (“Agreement”) is made by and between GenMark Diagnostics,…
To view the full exhibit click
About GENMARK DIAGNOSTICS, INC. (NASDAQ:GNMK)
GenMark Diagnostics, Inc. (GenMark) is a molecular diagnostics company. The Company focuses on developing and commercializing its eSensor detection technology. Its eSensor electrochemical technology detects multiple distinct biomarkers in a single sample. It sells its XT-8 instrument and related diagnostic and research tests (XT-8 system) in the United States. It has developed and intends to commercially launch its sample-to-answer ePlex instrument and its associated diagnostic tests, which it collectively refers to as its ePlex system, in Europe and the United States. It operates in the development, manufacturing, sales and support of instruments and molecular tests based on its eSensor detection technology segment. Over four of its diagnostic tests, which run on its XT-8 instrument, have received United States Food and Drug Administration clearance, including Cystic Fibrosis Genotyping Test, Warfarin Sensitivity Test, Thrombophilia Risk Test and Respiratory Viral Panel.